Clinical trial
Combination Chemotherapy (Methotrexate, L-asparaginase, Idarubicin and Dexamethasone) in Patients With Newly Diagnosed Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
NCT03599960 is registered in ClinicalTrials.gov with Centre Hospitalier Universitaire de Besancon as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Combination Chemotherapy (Methotrexate, L-asparaginase, Idarubicin and Dexamethasone) in Patients With Newly Diagnosed Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- Lead sponsor
- Centre Hospitalier Universitaire de Besancon
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- May 2, 2019
- Completion date
- November 30, 2024
- Enrollment
- 26 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
blastic plasmacytoid dendritic cell neoplasm (bpdcn)